TME Pharma NV is a clinical-stage biopharmaceutical company, which focuses on therapeutics targeting the tumor microenvironment or TME. The firm is active in pioneering the development of a new class of proprietary therapeutics called Spiegelmers. Its pipeline includes NOX-A12 and NOX-E36. The company was founded on January 16, 2015 and is headquartered in Berlin, Germany.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company